The Role of Elacestrant in ER+/HER2– Advanced Breast Cancer Harboring ESR1 Mutations

Hope S. Rugo, MD, and Seth Wander, MD, PhD, explore the clinical role of elacestrant (Orserdu) in estrogen receptor/HER2-negative advanced breast cancer with ESR1 mutations following the agent’s January 2023 FDA approval for use in patients with disease progression following at least 1 line of endocrine therapy. They discuss how this oral SERD addresses endocrine resistance and fits into current treatment algorithms. Rugo and Wander place elacestrant’s activity in context of evolving post-CDK4/6 inhibitor therapeutic options.